A recent study showed lower S100B levels from patients with stages I and II (primary melanoma) than stage III (regional melanoma) and stage IV (metastatic melanoma), the levels of S100B being the highest in patients with metastatic melanoma [145]. Here, S100B is linked to metastatic melanoma.